Paper Review Records
All Paper Review Records
18 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
129
days
Targeting the proteasome in Leishmania donovani : developments from preclinical to Phase I and II trials
Authors
Shyam Sundar; Sarita Singh; Priya Maurya; Vishal Kumar Singh; Rajiv KumarShow moreShow less
Affiliations
1. Banaras Hindu UniversityShow moreShow less
26
days
Dual antigen targeting in extramedullary multiple myeloma
Authors
Binish Javed; Shaji KumarShow moreShow less
Affiliations
1. Mayo ClinicShow moreShow less
65
days
Evaluating early systemic therapies in the neoadjuvant setting for the treatment of urological cancers
Authors
Panagiotis Velissarios Stamatakos; Charalampos Fragkoulis; Nikolaos Kontolatis; Konstantinos Gklinos; Christoforos Kourouniotis; Athanasios DellisShow moreShow less
Affiliations
1. General Hospital of Athens “Korgialeneio Benakeio Hellenic Red Cross”; 2. General Hospital of Athens “G. Gennimatas”; 3. National and Kapodistrian University of Athens, Hospital of Athens “Aretaieion”Show moreShow less
140
days
Safety, pharmacokinetics, pharmacodynamics and target-mediated drug disposition modeling of TST002, a sclerostin antibody, in men and postmenopausal women with low bone mineral density
Authors
Sufeng Zhou; Xiufen Zhu; Yuchen Sheng; Lu Wang; Feng Shao; Hua LinShow moreShow less
Affiliations
1. The First Affiliated Hospital with Nanjing Medical University; 2. Nanjing Medical University; 3. The Affiliated Hospital of Nanjing University Medical SchoolShow moreShow less
208
days
Emerging therapeutic strategies and clinical development of investigational agents for conventional chondrosarcoma
Authors
Carlos Torrado; Anthony P. ConleyShow moreShow less
Affiliations
1. The University of Texas MD Anderson Cancer CenterShow moreShow less
111
days
Peripheral cannabinoid-1 receptor antagonists in clinical development: therapeutic potential for the management of obesity and related metabolic disorders
Authors
Jonanne Talebloo; Esha Chawla; Donya Shahamati; Swas Shiv; Kishore M. GaddeShow moreShow less
Affiliations
1. University of California Irvine School of Medicine; 2. Vanderbilt University School of Medicine; 3. University of California Irvine; 4. Boston UniversityShow moreShow less
FAQ
How long does EXPERT OPINION ON INVESTIGATIONAL DRUGS take to review a manuscript?
As of 2026-11-19, CrushSCI has 18 complete review records for EXPERT OPINION ON INVESTIGATIONAL DRUGS. The fastest paper went from submission to acceptance in 26 days (Dual antigen targeting in extramedullary multiple myeloma, received 2026-09-10, accepted 2026-10-06); the slowest took 334 days. The average is 129 days and the median is 130 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
